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both the volume and centre of the GTV. The process of using 
co-registering MR-CT images increases the uncertainty and 
leads to larger volumes when compared to GTV delineation 
using MR only. Data from additional observers will help 
quantify the magnitude of GTV delineation uncertainties. The 
limitation of having outlines from a single non-expert 
observer will be addressed in the final publication. 
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Purpose or Objective: To evaluate long-term clinical results 
after intensity modulated radiotherapy technique (IMRT) on 
vaginal vault in post-operative low-risk endometrial cancer 
patients. 
 
Material and Methods: Patients enrolled in two sequential 
trials (June 2006-October 2014) were analysed. A radiopaque 
methacrylate vaginal applicator was placed in the vagina. 
Patients were planned in supine position and immobilized 
using a vacuum cushion. Each patient was instructed to 
follow a protocol of controlled bladder filling and rectal 
emptying. Three radiopaque markers (1 mm diameter) fixed 
on the applicator allowed to improve visualization on portals 
imaging. Radiotherapy was delivered on the upper two thirds 
of the residual vagina (CTV), daily identified by the 
radiopaque markers. A 5 mm isotropic margin was added to 
the CTV in order to define the planning target volume (PTV). 
A 7 beams step and shoot IMRT technique was used by means 
of Plato Sunrise and Ergo++ treatment planning systems. 
25Gy/5Gy per fraction in the first trial and 30Gy/6Gy in the 
second one were the doses delivered to PTV. Toxicity was 
scored by the CTC-AE v.3.0 scale. 
 
Results: 23 patients (median age 63 years, range 49-88; stage 
IA: 69.6%, IB: 21.7%, II: 8.7%; grading G1: 3; G2: 17; G3: 3) 
were included in this analysis. Seven patients received 
25Gy/5Gy and 16 received 30 Gy/6Gy per fraction. Proctitis 
and dysuria were the most common toxicities. Twelve 
patients (52.2%) developed late mild toxicity (G2: 1 rectal 
bleeding and 1 atrophic skin with plaque lesions). The most 
common late toxicity was G1 vulvar telangiectasia (26%), 
while 3 patients developed G1 vaginal stenosis (Table 1). 
 
 
With a median follow-up of 52 months (range 4-103) no 
vaginal recurrence was observed (5-year local control: 100%), 
while 4 patients developed pelvic or distance relapse (5-year 
disease-free survival: 86.4%). Five-year overall survival was 
100%. 
 
Conclusion: Endovaginal brachytherapy studies reported 0-
5.2% late severe toxicity. Most toxicities were vaginal and 
urethral stenosis or rectal vaginal fistula, not observed in our 
study. In conclusion postoperative IMRT on vaginal vault 
showed promising clinical long-term results. 
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Purpose or Objective: The current study aims to evaluate 
the outcomes in patients treated with radical radiotherapy 
for cervical cancer who received external beam radiotherapy 
(EBRT) boost in place of intracavitary brachytherapy (ICBT).  
 
Material and Methods: We performed a multicenter 
retrospective study on the patients with cervical cancer 
treated with external beam boost as a substitution of ICBT 
during the period of January 2005 through October 2012 in 11 
participating radiation oncology centers in Korea. Treatment 
outcome, prognostic factor, and toxicity were evaluated.  
 
Results: Seventy-five patients were identified. The median 
age of the patients was 58 years (range, 33-92 years). The 
clinical stages were I in 6, II in 34, III in 18, and IVA in 17 
patients. Concurrent chemotherapy was performed to 64 
patients (85.3%). Radiation doses were median 46 Gy (range, 
40-54 Gy) for whole pelvis and 24 Gy (range, 9-35 Gy) for 
tumor boost. Three-dimensional radiotherapy (in 24 patients) 
or intensity-modulated radiotherapy (in 51 patients) was used 
for tumor boost. On images taken 3-6 months after 
radiotherapy, 46 patients showed complete response (CR), 24 
had partial response, and 2 were found to have progressive 
disease. The median follow-up time was 33 months. Disease 
progression was found in 30 patients (40.0%). Among these 
patients, 21 (28.0%) showed local progression with a median 
time to progression of 29 months (range, 3-101 months). The 
5-year local progression-free survival (LPFS) rate was 70.0%. 
On uni- and multivariate analyses, treatment response at 3-6 
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months after radiotherapy was a significant factor for LPFS. 
Patients with CR had higher LPFS rate than the patients 
without CR (88.6% vs. 30.8%, at 5-year, p<0.01). Grade 3 
toxicity was found in 8 patients (5 hematologic, 2 urinary, 
and 1 skeletal) and grade 5 bowel toxicity was found in 1 
patient. 
 
Conclusion: In radical radiotherapy for cervical cancer, EBRT 
can be an option for tumor boost in cases where ICBT cannot 
be performed. Tumor response at 3-6 months after 
radiotherapy was a significant prognostic factor for local 
control.  
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Purpose or Objective: Patients with advanced endometrial 
cancer are a very heterogeneousgroup of patients in which 
theprognosis is influenced by thenumber of extrauterine 
locations,abdominal and nodal spread, typeof surgery, tumor 
residue and histology. 
 
Material and Methods: We studied 47 patients treated with 
SQTWAPI. The FIGOstaging was IIIAin 6 patients, IIIC in 22 and 
IVB in 16. The meanfollow-up for disease-freesurvival (DFS) 
was 32 months.In 26 patients werefound ≤ 3 extrauterine 
locations (≤3LE) and in 21 >3LE. Abdominal spread was 
presentin 26 and was not in 21, negative lymph nodespread in 
11 (G-), positivein 33 (G +) andunknown in 3 (G?). 
Combination of abdominal dissemination and lymph node 
spread (AG) was observed in19 patients, only abdominalin 7 
(SA), single nodal in 17 (SG) and noabdominal or nodal in 4 
(NAG). In 23 ovarian surgery was performed and in 24 it was 
suboptimal.In 8 patients remained tumor residue and 39 did 
not remain. 19 patients hadendometrioid histology and 28 
had a different one. Histological grade 1-2 in 11 and G3 in 36. 
 
Results: The 5-year DFS was respectively:≤3LE patients 
was69% vs 30%in> 3LE (p= 0.0445). Withabdominal spread 
73%vs 35% without(p = 0.05).Group (G-) 90%,group (G+) 47% 
andGroup (G?) 0%, (p = 0.0062).No residue 54%vs 34% (p = 
0.11). Group (AG) 22%, group(SG) 65%, group(SA) 85%,Group 
(NAG) 100% (p = 0.0185). With ovarian protocolsugery 42% 
and without it 62% (p = 0.23). 
 
Conclusion: The number of extrauterine locations, lymph 
node spread, abdominal dissemination and the combination 
of both influenced the SLE. 
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Purpose or Objective: The only imaging modalities without 
pathological confirmation are used to assess lymph node (LN) 
metastases and to perform radiation therapy (RT) planning 
for patients with uterine cervical cancer treated with 
concomitant chemoradiotherapy (CCRT) or RT alone. The aim 
of this study was to evaluate the accuracy of computed 
tomography (CT), magnetic resonance imaging (MRI) and 
positron emission tomography-computed tomography 
(PET/CT) in predicting pelvic LN metastases. 
 
Material and Methods: From January 2009 to March 2015, 
one hundred fifty six patients with International Federation 
of Obstetrics and Gynecology (FIGO) Stage IA1-IIB uterine 
cervical cancer who underwent radical hysterectomy and 
pelvic lymphadenectomy, and CT, MRI and PET/CT before 
surgery were included in this study. The Criteria for LN 
metastases were a LN diameter of 1cm or more at CT and MRI 
and a focally increased FDG uptake greater than SUVmax 3.0 
at PET/CT. The sensitivity, specificity, positive predictive 
value (PPV), negative predictive value (NPV) and accuracy for 
pelvic LN metastases were estimated on the basis of imaging 
and postsurgical pathological findings. Chi square test and 
McNemar's test was used to compare the sensitivity and 
specificity of imaging modalities for the detection of 
metastatic pelvic LN. A P value≤0.05 was considered 
statistically significant. 
 
Results: Among 156 patients, 35 (22%) had pelvic LN 
metastasis on postsurgical pathological findings. There was 
no pelvic LN metastasis for stage IA. The rates of pelvic LN 
metastasis on pathological findings for stage IB, IIA and IIB 
were 19%, 45%, 67%, respectively. The sensitivity, specificity, 
PPV, NPV and accuracy for detection of pelvic LN metastases 
were 48%, 87%, 39%, 91% and 81% for CT; 28%, 97%, 59%, 89% 
and 87% for MRI; and 43%, 90%, 43%, 90% and 83% for PET/CT, 
respectively. The sensitivity was highest for PET/CT, the 
specificity, highest for MRI and the accuracy, highest for MRI. 
The difference between single and multiple metastases on 
image studies to predict LN metastasis was not statistically 
significant (P=0.271). 
 
Conclusion: CT, MRI and PET/CT showed low sensitivity and 
high specificity. The accuracies (greater than 80%) of the 
three imaging modalities were acceptable for RT planning for 
patients treated with CCRT or RT alone. More efforts are 
necessary to improve sensitivity in predicting pelvic LN 
metastases. 
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Purpose or Objective: The outcomes among patients with 
endometrial cancer (EC) are generally favorable. However, 
certain risk factors, such as age, comorbidities, FIGO stage, 
histology type, myometrial infiltration and histology grade, 
may influence survival and prognosis. The aim of this study 
was to analyze the impact of prognostic factors on disease-
free survival (DFS) and overall survival (OS) in patients 
treated with adjuvant radiotherapy. 
 
Material and Methods: We reviewed the records of patients 
diagnosed with EC and received adjuvant radiation therapy. 
The period of recruitment was from January 2001 to 
December 2014. This included epidemiological, clinical and 
treatment characteristics. Statistical analyses, survival 
curves were generated using the Kaplan-Meier technique, and 
differences were tested with the log-rank test. Multivariate 
